Ordering
Available Variants10 mg
CHA.24640-10mg
Price
€92.80
Available – Dispatch in 14 days
50 mg
CHA.24640-50mg
Price
€288.00
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.24640-10mg | €92.80 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.24640-50mg | €288.00 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C14H22N6O5·HCl · xH2O |
|---|---|
| CAS Number | 175865-59-5 |
| Molecular Weight | 390.82 (anhydrous basis) |
| UNSPSC Code | 12352200 |
| PubChem Substance ID | 329825218 |
| NACRES | NA.77 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
| Storage condition | desiccated |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
Valganciclovir hydrochloride hydrate, with a chemical formula of C14H22N6O5.HCl.xH2O and a CAS number of 175865-59-5, is a potent antiviral agent. It is a prodrug of ganciclovir, which is a nucleoside analogue that inhibits viral DNA synthesis. Upon administration, valganciclovir is rapidly converted to ganciclovir, which then acts as a substrate for viral DNA polymerase, resulting in the termination of viral DNA elongation. This mechanism of action makes valganciclovir hydrochloride hydrate effective against cytomegalovirus (CMV) infections, particularly in immunocompromised patients such as organ transplant recipients. The hydrate form of the compound is used in pharmaceutical formulations to enhance stability and bioavailability, allowing for improved treatment outcomes in patients with CMV retinitis and other related conditions. Its efficacy and safety profile have been well-established in clinical trials.
